Jubilant Pharmova Limited (JUBLPHARMA.BO)
INR 881.1
(-0.37%)
INR 881.1
(-0.37%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 61.27 Billion INR | 6.29% |
| 2022 | 57.64 Billion INR | 23.33% |
| 2021 | 46.74 Billion INR | 11.92% |
| 2020 | 41.76 Billion INR | -39.63% |
| 2019 | 69.17 Billion INR | 3.88% |
| 2018 | 66.59 Billion INR | 19.29% |
| 2017 | 55.82 Billion INR | -1.23% |
| 2016 | 56.51 Billion INR | -4.14% |
| 2015 | 58.96 Billion INR | -2.44% |
| 2014 | 60.43 Billion INR | -0.59% |
| 2013 | 60.79 Billion INR | 5.12% |
| 2012 | 57.83 Billion INR | 6.17% |
| 2011 | 54.47 Billion INR | 1.68% |
| 2010 | 53.57 Billion INR | 15.77% |
| 2009 | 46.27 Billion INR | -10.79% |
| 2008 | 51.87 Billion INR | 75.66% |
| 2007 | 29.53 Billion INR | 26.36% |
| 2006 | 23.37 Billion INR | 89.51% |
| 2005 | 12.33 Billion INR | 63.78% |
| 2004 | 7.52 Billion INR | 14.12% |
| 2003 | 6.59 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 59.97 Billion INR | 210.63% |
| 2024 Q1 | -54.21 Billion INR | -188.47% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 61.27 Billion INR | 0.0% |
| 2023 Q2 | 59.98 Billion INR | 0.0% |
| 2023 FY | 61.27 Billion INR | 6.29% |
| 2022 Q2 | 52.33 Billion INR | 0.0% |
| 2022 Q4 | 57.64 Billion INR | 0.0% |
| 2022 FY | 57.64 Billion INR | 23.33% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 43.73 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 46.74 Billion INR | 0.0% |
| 2021 FY | 46.74 Billion INR | 11.92% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 41.76 Billion INR | -39.63% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 41.76 Billion INR | 0.0% |
| 2020 Q2 | 64.07 Billion INR | 0.0% |
| 2019 Q2 | 66.62 Billion INR | 0.0% |
| 2019 FY | 69.17 Billion INR | 3.88% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 69.17 Billion INR | 0.0% |
| 2018 FY | 66.59 Billion INR | 19.29% |
| 2018 Q4 | 66.59 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 61.22 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 55.82 Billion INR | -1.23% |
| 2017 Q2 | 56.72 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 55.82 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 56.51 Billion INR | -4.14% |
| 2016 Q2 | 54.94 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 56.51 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 58.96 Billion INR | -2.44% |
| 2015 Q4 | 58.96 Billion INR | 0.0% |
| 2015 Q2 | 61.15 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q4 | 60.43 Billion INR | 0.0% |
| 2014 FY | 60.43 Billion INR | -0.59% |
| 2014 Q2 | 61.81 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q4 | 60.79 Billion INR | 0.0% |
| 2013 FY | 60.79 Billion INR | 5.12% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 62.08 Billion INR | 0.0% |
| 2012 Q4 | 57.83 Billion INR | 0.0% |
| 2012 FY | 57.83 Billion INR | 6.17% |
| 2011 FY | 54.47 Billion INR | 1.68% |
| 2011 Q4 | 54.47 Billion INR | 0.0% |
| 2010 FY | 53.57 Billion INR | 15.77% |
| 2009 FY | 46.27 Billion INR | -10.79% |
| 2008 FY | 51.87 Billion INR | 75.66% |
| 2007 FY | 29.53 Billion INR | 26.36% |
| 2006 FY | 23.37 Billion INR | 89.51% |
| 2005 FY | 12.33 Billion INR | 63.78% |
| 2004 FY | 7.52 Billion INR | 14.12% |
| 2003 FY | 6.59 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -276.519% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 59.743% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -1082.69% |
| Granules India Limited | 22.95 Billion INR | -166.938% |
| Indoco Remedies Limited | 10.34 Billion INR | -492.46% |
| Achyut Healthcare Limited | 2.01 Million INR | -3043814.555% |
| Ajanta Pharma Limited | 10.71 Billion INR | -472.103% |
| Alkem Laboratories Limited | 48.6 Billion INR | -26.065% |
| Alpa Laboratories Limited | 307.12 Million INR | -19851.029% |
| Brooks Laboratories Limited | 248.6 Million INR | -24547.528% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -1573.646% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -1158.796% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -2805.563% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 42.717% |
| Eris Lifesciences Limited | 38.26 Billion INR | -60.118% |
| FDC Limited | 3.7 Billion INR | -1551.943% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 5.893% |
| Gufic Biosciences Limited | 5.59 Billion INR | -994.216% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -2576.35% |
| Ipca Laboratories Limited | 33.74 Billion INR | -81.591% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -20547.661% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -1960.382% |
| Lasa Supergenerics Limited | 541.92 Million INR | -11206.731% |
| Laurus Labs Limited | 42.71 Billion INR | -43.45% |
| Lupin Limited | 96.23 Billion INR | 36.33% |
| Mankind Pharma Limited | 23.87 Billion INR | -156.649% |
| Medicamen Biotech Limited | 940.36 Million INR | -6415.967% |
| Medico Remedies Limited | 438.24 Million INR | -13881.709% |
| Megasoft Limited | 1.85 Billion INR | -3206.491% |
| NATCO Pharma Limited | 10.53 Billion INR | -481.789% |
| Piramal Pharma Limited | 74 Billion INR | 17.202% |
| RPG Life Sciences Limited | 1.38 Billion INR | -4339.502% |
| Sigachi Industries Limited | 2.53 Billion INR | -2320.687% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 66.621% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -2912.149% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -5158.618% |
| Unichem Laboratories Limited | 8.06 Billion INR | -659.352% |
| Wanbury Limited | 3.15 Billion INR | -1841.805% |
| Windlas Biotech Limited | 1.76 Billion INR | -3376.145% |
| ZIM Laboratories Limited | 2.08 Billion INR | -2844.787% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 14.651% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -1473.994% |
| Divi's Laboratories Limited | 18.99 Billion INR | -222.665% |
| Hester Biosciences Limited | 3.59 Billion INR | -1604.556% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -2292.394% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -7717.316% |
| Bal Pharma Limited | 2.51 Billion INR | -2339.955% |
| Strides Pharma Science Limited | 37.68 Billion INR | -62.615% |
| Venus Remedies Limited | 1.39 Billion INR | -4299.339% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -642.652% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -446.207% |
| Shilpa Medicare Limited | 12.93 Billion INR | -373.799% |
| Aarti Drugs Limited | 11.5 Billion INR | -432.632% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -868.162% |
| Suven Life Sciences Limited | 148.62 Million INR | -41128.359% |
| Ind-Swift Limited | 13.45 Billion INR | -355.468% |
| Valiant Laboratories Limited | 1.05 Billion INR | -5690.076% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -472.226% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -333.222% |
| Themis Medicare Limited | 1.88 Billion INR | -3146.286% |
| Hikal Limited | 12.99 Billion INR | -371.523% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 25.321% |
| Sequent Scientific Limited | 8.27 Billion INR | -640.538% |
| Novartis India Limited | 1.8 Billion INR | -3302.032% |
| Wockhardt Limited | 39.87 Billion INR | -53.684% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -21116.832% |
| Neuland Laboratories Limited | 5.49 Billion INR | -1014.364% |
| Morepen Laboratories Limited | 4.45 Billion INR | -1273.922% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -9416.325% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -3000.423% |